NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ATNF

180 Life Sciences Corp

Jul 07 • 04:00PM ET

0.7997

Dollar change -0.0809
Percentage change -9.19	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN BIIB ABBV VRTX GILD BMRN INCY ALNY NBIX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.38	Insider Own	47.75%	Shs Outstand	5.19M	Perf Week	-3.65%
Market Cap	4.85M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.69M	Perf Month	-25.21%
Enterprise Value	1.28M	PEG	-	EPS next Q	-	Inst Own	0.46%	Short Float	1.43%	Perf Quarter	-9.12%
Income	-15.48M	P/S	-	EPS this Y	-	Inst Trans	-8.60%	Short Ratio	0.29	Perf Half Y	-56.06%
Sales	0.00M	P/B	0.54	EPS next Y	-	ROA	-98.96%	Short Interest	0.04M	Perf YTD	-56.06%
Book/sh	1.49	P/C	1.30	EPS next 5Y	-	ROE	-221.23%	52W High	17.75 -95.49%	Perf Year	-51.53%
Cash/sh	0.61	P/FCF	-	EPS past 3/5Y	60.23% 55.37%	ROIC	-200.79%	52W Low	0.66 21.57%	Perf 3Y	-99.75%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	12.87% 9.29%	Perf 5Y	-99.98%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	87.16%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.96	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.02	EPS Q/Q	60.05%	SMA20	-13.36%	Beta	0.21	Target Price	1520.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-20.58%	Rel Volume	1.76	Prev Close	0.88
Employees	3	LT Debt/Eq	0.00	Earnings	-	SMA200	-51.44%	Avg Volume	133.73K	Price	0.80
IPO	Jun 27, 2017	Option/Short	No / Yes	EPS/Sales Surpr.	84.62% -	Trades		Volume	235,697	Change	-9.19%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-21	Initiated	Maxim Group	Buy	$11

Jul-01-25 07:30AM	180 Life Sciences Corp. Announces Strengthening of Legacy Intellectual Property Assets (ACCESSWIRE)
May-01-25 09:30AM	180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction (ACCESSWIRE) +49.44%
Apr-30-25 08:30AM	180 Life Sciences Corp. Announces Share Repurchase (ACCESSWIRE)
Dec-27-24 09:00AM	180 Life Sciences Corp. Announces Pricing of $2.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under NASDAQ Rules (ACCESSWIRE) -24.03%
Dec-12-24 08:00AM	180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules (ACCESSWIRE) -14.16%
08:00AM	Loading…
Dec-04-24 08:00AM	180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors (ACCESS Newswire)
Oct-31-24 08:00AM	180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration (ACCESSWIRE)
Oct-29-24 08:00AM	180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors (ACCESSWIRE)
Oct-25-24 09:00AM	Elray Resources Announces Strategic Sale of Crypto iGaming Technology (GlobeNewswire) +9.79%
Oct-17-24 10:52AM	180 Life Sciences' Brave Decision To Switch to the iGaming Industry (GuruFocus.com) -33.08%
Oct-16-24 08:00AM	180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform (ACCESSWIRE) +325.66%
Oct-09-24 08:30AM	180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector (ACCESSWIRE) +16.10%
Oct-03-24 08:30AM	180 Life Sciences Corp. - Corporate Updates (ACCESSWIRE)
Sep-12-24 04:15PM	180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer (GlobeNewswire) +13.64% -9.50%
Jul-30-24 08:00AM	180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake (GlobeNewswire)
08:00AM	Loading…
Jul-23-24 08:00AM	180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (GlobeNewswire)
Jul-02-24 08:30AM	180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (GlobeNewswire) +10.00%
May-16-24 11:53AM	ATNF Stock Earnings: 180 Life Sciences Reported Results for Q1 2024 (InvestorPlace) -14.95%
Mar-14-24 08:30AM	180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Feb-26-24 07:00AM	180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire) +5.49%
Dec-04-23 09:00AM	180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives (GlobeNewswire)
Nov-28-23 09:00AM	180 Life Sciences Announces Review of Strategic Alternatives (GlobeNewswire) +7.70%
Aug-14-23 04:29PM	180 Life Sciences Corp. Announces Closing of $3 Million Public Offering (GlobeNewswire)
Aug-10-23 08:46AM	180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering (GlobeNewswire) -16.73%
Aug-07-23 09:00AM	180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake (GlobeNewswire)
Aug-03-23 08:00AM	180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytrens Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA (GlobeNewswire)
Jul-31-23 08:00AM	180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite (GlobeNewswire)
Apr-10-23 04:30PM	180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Apr-05-23 01:00PM	180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -19.66%
Feb-27-23 08:30AM	180 Life Sciences Announces Presentation at the Gordon Conference (GlobeNewswire) +5.51%
07:30AM	Loading…
Feb-23-23 07:30AM	180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytrens Disease Treatment and Application (GlobeNewswire) -10.82%
Feb-22-23 04:30PM	180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial (GlobeNewswire)
Jan-25-23 08:45AM	180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytrens Disease (GlobeNewswire) +33.75%
Jan-17-23 08:00AM	180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom (GlobeNewswire)
Jan-05-23 08:30AM	180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +12.33%
Jan-04-23 08:30AM	180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytrens Disease (GlobeNewswire) -17.36%
Dec-29-22 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders (GlobeNewswire) +13.86%
Dec-23-22 08:00AM	180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -21.52%
Dec-20-22 02:11PM	180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -15.85%
Dec-16-22 09:00AM	180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire) -11.67%
Nov-30-22 05:00PM	180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytrens Contracture (GlobeNewswire)
Nov-21-22 08:30AM	180 Life Sciences to Participate in A.G.P.s Virtual Biotech Conference to be Held November 30 December 1, 2022 (GlobeNewswire) -12.87%
Nov-15-22 12:37PM	CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytrens Disease (GlobeNewswire) +12.02%
08:00AM	Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytrens Disease (GlobeNewswire)
Sep-26-22 08:30AM	180 Life Sciences Issues Letter to Stockholders (GlobeNewswire)
Aug-22-22 08:30AM	180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder (GlobeNewswire) -10.53%
Jul-27-22 08:30AM	180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp. (GlobeNewswire)
Jul-21-22 08:00AM	180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering (GlobeNewswire) +5.65%
Jul-18-22 08:30AM	180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering (GlobeNewswire)
Jun-22-22 04:05PM	180 Life Sciences Corp. Issues Letter to Stockholders (GlobeNewswire)
Jun-14-22 04:15PM	180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytrens Disease (GlobeNewswire) -34.00%
May-31-22 08:30AM	180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytrens Disease (GlobeNewswire) +18.25%
May-02-22 08:00AM	REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytrens Disease Study Results in The Lancet Rheumatology (GlobeNewswire) -20.75%
Apr-29-22 06:32PM	180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytrens Disease Study Results in The Lancet Rheumatology (GlobeNewswire) +22.54%
Feb-17-22 08:30AM	180 Life Sciences Corp. Forms Scientific Advisory Board (GlobeNewswire) -6.61%
Jan-31-22 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders (GlobeNewswire) +7.12%
Dec-28-21 11:00AM	180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022 (GlobeNewswire) -5.75%
Dec-15-21 08:15AM	180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases (GlobeNewswire)
Dec-12-21 06:06AM	Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares (Simply Wall St.)
Dec-10-21 05:15PM	180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of Shares (GuruFocus.com)
Dec-06-21 08:15AM	180 Life Sciences Provides Follow-Up Information on Oxford University and the Companys Successful Dupuytrens Phase 2b Clinical Trial Results (GlobeNewswire) +7.95%
Dec-01-21 02:45PM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial (GlobeNewswire) -20.85%
02:26PM	180 Life Sciences: Positive Data From Dupuytrens Disease Study Could Be a Big Catalyst, Says Analyst (TipRanks)
Nov-22-21 08:30AM	180 Life Sciences Corp. Expands Patent Portfolio (GlobeNewswire)
Nov-18-21 08:15AM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium (GlobeNewswire) +9.86%
Nov-03-21 12:06PM	180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer (GlobeNewswire)
Oct-26-21 08:30AM	180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules (GlobeNewswire)
Sep-30-21 08:30AM	180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio (GlobeNewswire) +5.66%
Sep-20-21 08:00AM	Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications (GlobeNewswire) -6.29%
Aug-30-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders (GlobeNewswire)
Aug-24-21 08:30AM	180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement (GlobeNewswire)
Aug-19-21 09:00AM	180 Life Sciences Corp. Announces $15.0 Million Private Placement (GlobeNewswire) -25.73%
08:10AM	Is 180 Life Sciences Corp.'s (NASDAQ:ATNF) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Aug-02-21 08:00AM	Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021 (GlobeNewswire)
Jul-29-21 08:00AM	180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-28-21 08:15AM	180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue (GlobeNewswire)
Jul-20-21 08:00AM	180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) (GlobeNewswire)
Jul-12-21 09:51AM	180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2) (GlobeNewswire) +9.75%
Jul-07-21 08:00AM	180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal (GlobeNewswire)
Jun-28-21 08:15AM	180 Life Sciences Joins Russell Microcap® Index (GlobeNewswire)
08:00AM	180 Life Sciences Files Plan with Nasdaq Related to Delayed Quarterly Report on Form 10-Q and Form 10-K (GlobeNewswire)
Jun-10-21 09:12AM	180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors (GlobeNewswire)
Jun-01-21 08:00AM	180 Life Sciences Corp. to Present at LD Micro Invitational XI (GlobeNewswire) +8.90%
May-28-21 08:00AM	180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors (GlobeNewswire) +7.96%
May-21-21 04:45PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q (GlobeNewswire) +10.61%
Apr-20-21 08:00AM	180 Life Sciences Corp. Announces Collection of All Patient Data for Phase 2b Dupuytrens Disease Trial (GlobeNewswire)
Apr-19-21 05:00PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K (GlobeNewswire) -16.53%
Apr-14-21 08:15AM	180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021 (GlobeNewswire)
Mar-26-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics (GlobeNewswire) +18.57%
Mar-25-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters (GlobeNewswire) +13.65%
Mar-24-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders (GlobeNewswire)
Mar-08-21 01:30PM	180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC (GlobeNewswire) +5.46%
Feb-24-21 04:00PM	180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement (GlobeNewswire) +11.06% -10.37%
Feb-19-21 09:00AM	180 Life Sciences Corp. Announces $11.7 Million Private Placement (GlobeNewswire) -13.46%
Feb-17-21 12:00AM	Do Insiders Own Lots Of Shares In 180 Life Sciences Corp. (NASDAQ:ATNF)? (Simply Wall St.) -5.45%
Jan-11-21 08:00AM	180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference (Newsfile) +5.06%
Jan-05-21 02:50PM	180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference (GlobeNewswire) +7.17%
Dec-03-20 11:08AM	180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST (GlobeNewswire)
Nov-24-20 10:00AM	180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020 (GlobeNewswire) -6.93%
Nov-23-20 08:30AM	180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants (GlobeNewswire) +17.44%

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATNF

180 Life Sciences Corp

Upgrade your FINVIZ experience